Mesenchymal Stem Cells Show Promise in Gene Therapy for Gastric Cancer

Strategic Insights -

Researchers have made a significant discovery in the fight against gastric cancer, a leading cause of mortality worldwide. According to a recent study published in Drug Design, Development and Therapy, mesenchymal stem cells (MSCs) have shown great potential in delivering gene therapy for gastric cancer treatment. The study, conducted by a team of researchers from Nanchang University, found that MSCs can target gastric cancer cells and inhibit their growth.

Key Takeaways:

  • The study utilized MSCs to deliver the NK4 gene, which targets and inhibits the growth of gastric cancer cells.
  • The results showed that MSCs migrated preferably to gastric cancer cells in vitro and accumulated in tumor tissues after systemic injection.
  • Tumor growth was significantly suppressed in mice treated with MSCs-NK4, and microvessel density of tumor xenografts was decreased, and tumor cellular apoptosis was significantly induced.
  • The study concluded that MSC-based NK4 gene therapy is a promising approach for gastric cancer treatment and warrants further investigation in humans.
  • The researchers found that MSCs are a better vehicle for NK4 gene therapy than lentiviral vectors.

Statistics:

  • Gastric cancer is the third leading cause of worldwide cancer mortality.
  • 8% of global cancer deaths are attributed to gastric cancer (Source: World Health Organization).
  • The study used nude mice bearing gastric cancer xenografts to evaluate the efficacy of MSC-based NK4 gene therapy.
  • The results showed a significant reduction in tumor growth and increase in tumor cellular apoptosis in mice treated with MSCs-NK4.
  • The study demonstrated that MSC-based NK4 gene therapy can inhibit the growth of gastric cancer xenografts by 62% (Source: Drug Design, Development and Therapy).

Sources:

  • Jiangxi, People's Republic of China: "Mesenchymal stem cells (MSCs) have been recognized as promising delivery vehicles for gene therapy of tumors."
  • Nanchang University: "NK4 is an antagonist of hepatocyte growth factor receptors (Met) which are often aberrantly activated in gastric cancer and thus represent a useful candidate for targeted therapies."
  • Drug Design, Development and Therapy: "Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. Drug Design, Development and Therapy, 2014;8():2449-62"